NCT01158183

Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis

Real-World Betaseron® Outcomes Study (ROBUST): A Twelve-month, US Prospective, Observational, Open-label, Single-arm, Multi-center Outcomes Study of Interferon β-1b (Betaseron®) Given Every Other Day for Relapsing Forms of Multiple Sclerosis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 226 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

A Web based real world observational study in Relapsing-Remitting Multiple Sclerosis (RRMS) population capturing outcomes reported by patients and by the physicians during 12 months after initiating or resuming Betaseron.

Conditions

• Multiple Sclerosis, Relapsing-Remitting

Interventions

Type	Name	Description
DRUG	BAY86-5046_Interferon-beta-1b	Electronic questionnaires

Timeline

• Start date: 2007-07-01
• Primary completion: 2009-09-01
• Completion: 2009-09-01
• First posted: 2010-07-08
• Last updated: 2010-07-08

Locations

27 sites across 1 country: United States